title: Serologic laboratory findings in malignancy.
abstract: Autoantibodies are extremely promising diagnostic and prognostic biomarkers of cancer, and have the potential to promote early diagnosis and to make a large impact by improving patient outcome and decreasing mortality. Moreover, autoantibodies may be useful reagents in the identification of subjects at risk for cancer, bearing premalignant tissue changes. Great efforts are being made in many laboratories to validate diagnostic panels of autoantibodies with high sensitivity and specificity that could be useful in a clinical setting. It is likely that prospective studies of sufficiently large cohorts of patients and controls using high-throughput technology may allow the identification of biomarkers with diagnostic significance, and perhaps of discrete antigen phenotypes with clinical significance. The identification of TAAs may also be essential for the development of anticancer vaccines, because autoantibodies found in cancer sera target molecules involved in signal transduction, cell-cycle regulation, cell proliferation, and apoptosis, playing important roles in carcinogenesis. On this basis, molecular studies of antigenantibody systems in cancer promise to yield valuable information on the carcinogenic process. TAAs identified by serum antibodies in cancer sera can be natural immunogenic molecules, useful as targets for cancer immunotherapy. An important problem encountered in the practice of medicine is the identification of healthy individuals in the general population who unknowingly are at high risk of developing cancer. For the rheumatologist, a related problem is the identification of those patients with rheumatic diseases who are at high risk for developing a malignant process. These problems encountered in the fields of cancer and the rheumatic diseases can in the future be helped by new diagnostic instruments based on antibodies. The need for promoting the early diagnosis of cancer is a recognized major public health problem in need of significant research support for the validation of multiple promising but inconclusive studies, with the intention of producing diagnostic panels of autoantibodies in various types of cancers. Cancer developing in patients with rheumatic diseases is also an important problem requiring prospective longterm follow-up studies of patients with rheumatic diseases, particularly because some of the new biologic therapies seem to increase the cancer risk. It is possible that a panel of autoantibodies common to patients with cancer and the rheumatic diseases may prove to be of value in the identification of those patients with ADs at high risk for neoplasms.
authors.affiliation: Division of Rheumatology, University Health Center, Wayne State University, 4201 Saint Antoine Pod 4H, Detroit, MI 48201, USA. fmadrid@med.wayne.edu
authors.forename: Félix Fernández
authors.initials: FF
authors.lastname: Madrid
authors.forename: Marie-Claire
authors.initials: MC
authors.lastname: Maroun
mesh_terms: D000974:Antibodies, Antinuclear / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D023281:Genomics / Q000379:methods; D006801:Humans; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000276:immunology; D010257:Paraneoplastic Syndromes / Q000097:blood / Q000276:immunology; D040901:Proteomics / Q000379:methods; D012698:Serologic Tests
chemical_list: D000974:Antibodies, Antinuclear; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins
references.citation: Springer Semin Immunopathol. 1998;19(3):345-62
references.pmid: 9540161
references.citation: J Biol Chem. 1992 May 5;267(13):8919-24
references.pmid: 1533622
references.citation: Immunol Rev. 2008 Apr;222:145-54
references.pmid: 18363999
references.citation: Clin Cancer Res. 2003 Nov 1;9(14):5120-6
references.pmid: 14613989
references.citation: Clin Cancer Res. 2002 Mar;8(3):752-8
references.pmid: 11895905
references.citation: Expert Rev Mol Diagn. 2002 May;2(3):226-32
references.pmid: 12050861
references.citation: Cancer Res. 2001 Nov 1;61(21):7908-12
references.pmid: 11691811
references.citation: Arthritis Rheum. 1989 Sep;32(9):1087-92
references.pmid: 2775319
references.citation: Anticancer Res. 2000 Nov-Dec;20(6B):4351-3
references.pmid: 11205270
references.citation: N Engl J Med. 2011 Aug 4;365(5):395-409
references.pmid: 21714641
references.citation: Hematol Oncol Clin North Am. 2008 Feb;22(1):53-65, vi
references.pmid: 18207065
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43
references.pmid: 12582023
references.citation: Ann Clin Lab Sci. 2001 Jul;31(3):253-8
references.pmid: 11508828
references.citation: Nature. 2003 Mar 13;422(6928):226-32
references.pmid: 12634796
references.citation: N Engl J Med. 1986 May 22;314(21):1360-8
references.pmid: 3517648
references.citation: Cancer Lett. 2005 Dec 18;230(2):187-98
references.pmid: 16297705
references.citation: Autoimmun Rev. 2010 Aug;9(10):691-4
references.pmid: 20621654
references.citation: Clin Exp Immunol. 2003 Nov;134(2):169-77
references.pmid: 14616773
references.citation: Arthritis Res Ther. 2011 Mar 02;13(2):R38
references.pmid: 21366908
references.citation: Cancer Cell. 2005 May;7(5):411-23
references.pmid: 15894262
references.citation: J Rheumatol. 1989 Jun;16(6):782-5
references.pmid: 2789286
references.citation: Semin Arthritis Rheum. 1995 Apr;24(5):323-58
references.pmid: 7604300
references.citation: Arthritis Rheum. 1979 Jul;22(7):796-8
references.pmid: 110340
references.citation: Clin Rheumatol. 2007 Jan;26(1):95-7
references.pmid: 16721493
references.citation: J Clin Immunol. 1986 May;6(3):194-204
references.pmid: 3487551
references.citation: Semin Oncol. 2011 Feb;38(1):119-27
references.pmid: 21362520
references.citation: Med Clin North Am. 1985 May;69(3):599-615
references.pmid: 3892193
references.citation: N Engl J Med. 2005 Sep 22;353(12):1224-35
references.pmid: 16177248
references.citation: Adv Immunol. 1989;44:93-151
references.pmid: 2646863
references.citation: Clin Exp Immunol. 2004 Jun;136(3):574-84
references.pmid: 15147363
references.citation: N Engl J Med. 1987 Oct 8;317(15):940-5
references.pmid: 2442611
references.citation: Trends Biotechnol. 2001 Jun;19(6):217-22
references.pmid: 11356283
references.citation: Clin Diagn Lab Immunol. 2004 Nov;11(6):1054-9
references.pmid: 15539505
references.citation: Lupus. 2000;9(7):515-20
references.pmid: 11035417
references.citation: Nature. 1982 Mar 18;296(5854):262-9
references.pmid: 6278322
references.citation: J Biol Chem. 1990 Feb 25;265(6):3177-82
references.pmid: 2406247
references.citation: Cancer Res. 2004 Aug 1;64(15):5089-96
references.pmid: 15289310
references.citation: Clin Exp Immunol. 1989 Mar;75(3):349-53
references.pmid: 2784742
references.citation: N Engl J Med. 1978 Nov 30;299(22):1203-7
references.pmid: 714080
references.citation: Gerontology. 2011;57(1):3-10
references.pmid: 20453490
references.citation: Cancer Immunol Immunother. 2003 Dec;52(12):715-38
references.pmid: 12920480
references.citation: Expert Rev Anticancer Ther. 2006 Aug;6(8):1215-23
references.pmid: 16925487
references.citation: Clin Chem. 1998 Sep;44(9):2015-30
references.pmid: 9733000
references.citation: Cancer Res. 2000 Apr 1;60(7):1777-88
references.pmid: 10766157
references.citation: J Rheumatol. 2004 Mar;31(3):419-21
references.pmid: 14994382
references.citation: J Clin Invest. 2001 Nov;108(10):1411-5
references.pmid: 11714730
references.citation: PLoS Genet. 2008 Apr 25;4(4):e1000024
references.pmid: 18437207
references.citation: Lupus. 2004;13(3):159-64
references.pmid: 15119543
references.citation: Am J Pathol. 1992 Apr;140(4):859-70
references.pmid: 1314027
references.citation: Nucleic Acids Res. 1985 Dec 20;13(24):8813-26
references.pmid: 3841204
references.citation: Clin Exp Immunol. 1975 Mar;19(3):417-22
references.pmid: 1081928
references.citation: Clin Rheumatol. 2011 Mar;30(3):373-80
references.pmid: 21225302
references.citation: Ann Rheum Dis. 1992 Apr;51(4):573-4
references.pmid: 1586268
references.citation: Ann Oncol. 2011 Feb;22(2):383-9
references.pmid: 20675559
references.citation: Nature. 2004 Nov 18;432(7015):332-7
references.pmid: 15549095
references.citation: Recent Results Cancer Res. 1978;64:288-91
references.pmid: 734210
references.citation: Cancer Res. 2003 Jun 15;63(12):3275-80
references.pmid: 12810659
references.citation: Expert Opin Biol Ther. 2007 Apr;7(4):493-507
references.pmid: 17373901
references.citation: Semin Arthritis Rheum. 2006 Apr;35(5):322-32
references.pmid: 16616155
references.citation: Ann Clin Lab Sci. 2000 Apr;30(2):179-83
references.pmid: 10807162
references.citation: Arthritis Res Ther. 2011 Apr 21;13(2):109
references.pmid: 21554754
references.citation: Semin Oncol. 1997 Jun;24(3):360-72
references.pmid: 9208890
references.citation: Nat Med. 2002 Mar;8(3):295-301
references.pmid: 11875502
references.citation: Nat Med. 1995 Jul;1(7):701-2
references.pmid: 7585154
references.citation: Arthritis Rheum. 2002 Apr;46(4):1019-27
references.pmid: 11953980
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9
references.pmid: 11504947
references.citation: Autoimmun Rev. 2010 Mar;9(5):A259-66
references.pmid: 19963079
references.citation: Cancer. 1999 Jan 15;85(2):302-8
references.pmid: 10023696
references.citation: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):817-26
references.pmid: 15279766
references.citation: Autoimmun Rev. 2008 May;7(5):352-8
references.pmid: 18486921
references.citation: Clin Exp Immunol. 1993 Mar;91(3):442-8
references.pmid: 8443966
references.citation: Cancer Immunol Immunother. 1997 Apr;44(2):112-6
references.pmid: 9177473
references.citation: Cancer Res. 1992 Aug 1;52(15):4168-74
references.pmid: 1322237
references.citation: Semin Arthritis Rheum. 1996 Apr;25(5):337-46
references.pmid: 8778989
references.citation: J Biol Chem. 1994 Feb 11;269(6):4240-6
references.pmid: 7508441
references.citation: Curr Opin Microbiol. 2000 Jun;3(3):298-302
references.pmid: 10851162
references.citation: Int J Cancer. 1990 Jul 15;46(1):35-8
references.pmid: 2142141
references.citation: Br J Cancer. 1995 Aug;72(2):447-51
references.pmid: 7640230
references.citation: Br J Cancer. 1999 Jan;79(1):59-64
references.pmid: 10408694
references.citation: Immunology. 1990 Jan;69(1):117-20
references.pmid: 2179128
references.citation: Int J Cancer. 1982 Oct 15;30(4):403-8
references.pmid: 6292117
references.citation: Nature. 1992 Jul 2;358(6381):15-6
references.pmid: 1614522
references.citation: Yale J Biol Med. 1958 Sep;31(1):40-7
references.pmid: 13593495
references.citation: Cancer Res. 2006 Jan 15;66(2):1181-90
references.pmid: 16424057
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):569-70
references.pmid: 21454417
references.citation: Eur J Hum Genet. 2006 Mar;14(3):257-8
references.pmid: 16391554
references.citation: Nature. 2008 Jul 24;454(7203):436-44
references.pmid: 18650914
references.citation: Immunol Res. 2006;34(3):177-92
references.pmid: 16891670
references.citation: J Clin Rheumatol. 2001 Feb;7(1):47-50
references.pmid: 17039089
references.citation: J Clin Invest. 1997 Oct 15;100(8):2133-7
references.pmid: 9329980
references.citation: Clin Exp Metastasis. 1993 Jan;11(1):37-44
references.pmid: 8422704
references.citation: Nucleic Acids Res. 2000 Jan 15;28(2):e3
references.pmid: 10606671
references.citation: Proc Natl Acad Sci U S A. 1995 May 23;92(11):5116-20
references.pmid: 7761458
references.citation: J Biol Chem. 1968 Oct 25;243(20):5354-60
references.pmid: 4883096
references.citation: Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6
references.pmid: 16488983
references.citation: Lab Invest. 1994 Jan;70(1):6-22
references.pmid: 8302019
references.citation: Nature. 2002 Dec 19-26;420(6917):860-7
references.pmid: 12490959
references.citation: Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):49-57
references.pmid: 9456243
references.citation: Nature. 1994 Feb 17;367(6464):645-8
references.pmid: 7509044
references.citation: Cancer Res. 1997 Jul 15;57(14):2847-50
references.pmid: 9230187
references.citation: Breast Cancer Res. 2007;9(4):212
references.pmid: 17705880
references.citation: Nat Rev Immunol. 2010 Aug;10(8):594-604
references.pmid: 20651746
references.citation: J Pharm Biomed Anal. 1989;7(2):155-68
references.pmid: 2488616
references.citation: N Engl J Med. 2003 Oct 16;349(16):1526-33
references.pmid: 14561795
references.citation: Immunol Today. 1990 Apr;11(4):122-9
references.pmid: 2187469
references.citation: Immunol Rev. 2004 Dec;202:275-93
references.pmid: 15546400
references.citation: Br J Cancer. 1999 Feb;79(5-6):927-32
references.pmid: 10070892
references.citation: Autoimmun Rev. 2009 May;8(6):529-32
references.pmid: 19185619
references.citation: Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37
references.pmid: 16931107
references.citation: Cancer Lett. 2009 Aug 18;281(1):8-23
references.pmid: 19091462
references.citation: Arthritis Rheum. 1987 Dec;30(12):1420-5
references.pmid: 3435570
references.citation: Thorax. 2008 Mar;63(3):228-33
references.pmid: 17932110
references.citation: Int J Cancer. 1987 Feb 15;39(2):185-9
references.pmid: 3542843
references.citation: Arthritis Rheum. 1997 May;40(5):980-2
references.pmid: 9153564
references.citation: J Immunol. 2002 Sep 1;169(5):2701-11
references.pmid: 12193744
references.citation: Autoimmun Rev. 2011 Feb;10(4):222-7
references.pmid: 20955822
references.citation: Br Med J. 1971 Nov 27;4(5786):511-3
references.pmid: 4942740
references.citation: J Invest Dermatol. 1993 Jan;100(1):116S-123S
references.pmid: 8423380
references.citation: Lancet. 1972 Aug 26;2(7774):436
references.pmid: 4115262
references.citation: Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3
references.pmid: 8524854
references.citation: Biochem Biophys Res Commun. 1968 Oct 10;33(1):177-81
references.pmid: 5696502
references.citation: Cancer Res. 2000 Jun 1;60(11):2756-9
references.pmid: 10850408
references.citation: Clin Exp Rheumatol. 2000 Mar-Apr;18(2):227-32
references.pmid: 10812496
references.citation: N Engl J Med. 1992 Feb 6;326(6):363-7
references.pmid: 1729618
references.citation: Am J Hematol. 1998 Feb;57(2):139-43
references.pmid: 9462546
references.citation: Autoimmun Rev. 2008 Feb;7(4):272-7
references.pmid: 18295729
references.citation: Medicine (Baltimore). 1991 Nov;70(6):360-74
references.pmid: 1659647
references.citation: Clin Lab Med. 2002 Jun;22(2):447-74
references.pmid: 12134471
references.citation: Autoimmun Rev. 2005 Apr;4(4):230-5
references.pmid: 15893717
references.citation: J Thorac Oncol. 2006 Jul;1(6):513-9
references.pmid: 17409910
references.citation: J Pathol. 2003 Jul;200(4):429-47
references.pmid: 12845611
references.citation: Clin Immunol Immunopathol. 1987 Feb;42(2):250-8
references.pmid: 3100119
references.citation: Immunol Lett. 2003 Jan 2;85(1):71-4
references.pmid: 12505200
references.citation: J Clin Lab Anal. 1991;5(1):49-53
references.pmid: 1999763
references.citation: Cancer Res. 2001 Sep 1;61(17):6331-4
references.pmid: 11522620
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2396-405
references.pmid: 18006929
references.citation: Clin Cancer Res. 1999 Jun;5(6):1393-400
references.pmid: 10389924
references.citation: Proc Natl Acad Sci U S A. 1990 Mar;87(5):1777-81
references.pmid: 2308937
references.citation: Ann Rheum Dis. 2001 May;60(5):433-41
references.pmid: 11302861
references.citation: Br J Cancer. 1998 Jun;77(11):1848-51
references.pmid: 9667657
references.citation: Arch Dermatol. 2006 Mar;142(3):371-6
references.pmid: 16549717
references.citation: Cancer Res. 1996 Jan 1;56(1):121-6
references.pmid: 8548751
references.citation: Clin Immunol. 2001 Feb;98(2):293-300
references.pmid: 11161987